Viridian Therapeutics Inc
1S1
Company Profile
Business description
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate VRDN-001 is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) being developed for the potential treatment for patients with thyroid eye disease.
Contact
221 Crescent Street
Suite 401
WalthamMA02453
USAT: +1 617 272-4600
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
94
Stocks News & Analysis
stocks
Why ASX miners will handily beat banks in the long-term
After a stellar run for banks, investors are wondering whether they can continue their outperformance or if a rotation into miners is imminent. There’s a good case that a switch is coming, and it may last decades, not just years.
stocks
How to avoid dividend disaster
Thinking about common reasons a company might stop paying a dividend can help income investors avoid disappointment.
video
Do you qualify as 'rich'?
Morningstar's Sim Mody speaks with Mark LaMonica about the varying definitions of rich.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,785.10 | 101.70 | 1.17% |
| CAC 40 | 8,001.97 | 110.29 | 1.40% |
| DAX 40 | 21,866.98 | 281.05 | 1.30% |
| Dow JONES (US) | 44,857.18 | 16.10 | -0.04% |
| FTSE 100 | 8,748.11 | 124.82 | 1.45% |
| HKSE | 20,891.62 | 294.53 | 1.43% |
| NASDAQ | 19,710.22 | 17.89 | 0.09% |
| Nikkei 225 | 39,066.53 | 235.05 | 0.61% |
| NZX 50 Index | 12,844.59 | 60.45 | -0.47% |
| S&P 500 | 6,070.37 | 8.89 | 0.15% |
| S&P/ASX 200 | 8,520.70 | 103.80 | 1.23% |
| SSE Composite Index | 3,270.66 | 41.17 | 1.27% |